Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).

9076Background: The efficacy of ICPi in NSCLC with RTD is unknown. Methods: 82 consecutive patients (pts) with RTD (non-EGFR/ALK) were selected from the Davidoff Cancer Center database. The correla...